| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_407ddd1ec7bc19606fe032d05c3f1ec6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ccdaa61ca12cc11fe709b69547e3379a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd87c4b827eaecf265f7887094e94e2b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2001-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dc6a71fcbcf38450f846d70718e912a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddb7d04ceee3895803bf84bb4d94a9c9 |
| publicationDate |
2002-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0235231-A1 |
| titleOfInvention |
Screening method using a g coupled receptor associated with a specific g protein |
| abstract |
The present invention relates to screening methods comprising use of an A2A receptor coupled to Golf to screen for agents selectively interacting with A2A receptor coupled to Golf. Using this as a drug target it is possible to find an antagonist or an agonist for adenosine A2A receptor coupled to Golf. In a pharmaceutical preparation this antagonist or agonist may be used for treatment of disorders linked to dopaminergic neurotransmission such as Parkinson's disease and Schizophrenia. Furthermore such a pharmaceutical preparation could be used for, for treatment of CNS diseases involving dopaminergic or GABA transmittor systems. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10613079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015301030-A1 |
| priorityDate |
2000-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |